Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size
Key suggestions from the report:
Although there are several approved therapies in the field of ophthalmology and oncology, the market is still witnessing the unmet need due to the strong prevalence of metastatic carcinomas indications. The VEGF inhibitors are known to demonstrate promising results in oncology and their efficacy is higher than conventional treatments. The high target affinity and specificity of VEGF inhibitors will fuel the market growth during the forecast period.
The VEGF inhibitors market has a substantial number of drugs treating cancer and eye disorders. However, some metastatic cancer does not respond to a monotherapy drug. Thus, the popularity of combination therapy is increasing as drugs treating cancer are most effective when given in combination therapy. In combination therapy, drugs working on different mechanisms act on the site, thereby decreasing the likelihood that resistant cancer cells will develop. Thus, the growing popularity of combination therapy will fuel the growth of the market during the forecast period.
- Oncology segment represented close to 56% of the overall volume in 2018 owing to the increasing prevalence of various cancers globally.
- Ophthalmology segment is likely to register a CAGR of close to 9% in terms of revenue from 2019 to 2023 on account of the high prevalence of ophthalmic conditions, such as AMD RVO.
- The North-American vascular endothelial growth factor inhibitors market accounted for more than 47% of the overall revenue in 2018, owing to the sales of approved VEGF inhibitors and the increasing prevalence of several cancer indications, including RCC, melanomas, and NSCLC.
- The VEGF inhibitors market is moderately concentrated with a few players occupying the market share. In addition, the promising pipeline and expected approvals of the drugs are expected to intensify the competition among vendors.
Although there are several approved therapies in the field of ophthalmology and oncology, the market is still witnessing the unmet need due to the strong prevalence of metastatic carcinomas indications. The VEGF inhibitors are known to demonstrate promising results in oncology and their efficacy is higher than conventional treatments. The high target affinity and specificity of VEGF inhibitors will fuel the market growth during the forecast period.
The VEGF inhibitors market has a substantial number of drugs treating cancer and eye disorders. However, some metastatic cancer does not respond to a monotherapy drug. Thus, the popularity of combination therapy is increasing as drugs treating cancer are most effective when given in combination therapy. In combination therapy, drugs working on different mechanisms act on the site, thereby decreasing the likelihood that resistant cancer cells will develop. Thus, the growing popularity of combination therapy will fuel the growth of the market during the forecast period.
Comments
Post a Comment